ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
full-year 2024 for its approved products Onpattro (patisiran), Amvuttra (vutrisiran), Givlaari (givosiran) and Oxlumo (lumasiran). The company also issued its net product revenue guidance for 2025 and outlined several key products and pipeline updates for the year. Both Onpattro and Amvuttra are approved for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. Givlaari is approved for the treatment of acute hepatic porphyria. Oxlumo is approved for treating primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. Amvuttra, Givlaari and Oxlumo have witnessed strong patient demand so far, while Onpattro sales are declining as more patients are switching to treatment wi
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.MarketBeat
- Alnylam CEO: New administration ushers in great season of uncertainty [CNBC]CNBC
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.MarketBeat
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.MarketBeat
- Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline GoalsBusiness Wire
ALNY
Earnings
- 10/31/24 - Beat
ALNY
Sec Filings
- 1/24/25 - Form 4
- 1/23/25 - Form 144
- 1/13/25 - Form 8-K
- ALNY's page on the SEC website